WELLINGTON, N.Z. — New Zealand’s medical regulator has approved its first coronavirus vaccine, and officials hope to begin giving shots to border workers by the end of March.
New Zealand has no community transmission of the virus, and border workers are considered the most vulnerable to catching and spreading the disease because they deal with arriving travelers, some of whom are infected.
Regulators on Wednesday gave provisional approval for the vaccine developed by Pfizer and BioNTech for people aged 16 and over.
However, New Zealand’s success in stamping out the virus also means it will need to wait longer than many other countries to get vaccine doses for the general population. Officials say they hope to begin general inoculations by midyear.
LONDON (AP) — A mammoth three-year public inquiry into the U.
FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.
Explore articles from the past and connect to your heritage!
Discover the benefits of a subscription including access to exclusive content, events, and more!
Have an idea for a story, or know of an event we should cover? We want to hear about it!
The National Herald is the paper of record of the Greek Diaspora community. Through independent journalism, we bring news to generations of Greek-Americans, with stories on the individual, community and international level. Visit and support our 106 year-old sister publication Εθνικός Κήρυξ.
To purchase a gift subscription, please log out of your account, and purchase the subscription with a new email ID.
Sign up to receive our daily email news briefing.
Sign up for a subscription to The National Herald,
starting as low as $1/week.
and receive more access to The National Herald
View our Terms of Service + Privacy Policy.
and receive more access to The National Herald
View our Terms of Service + Privacy Policy.
We use cookies on our site to personalize your experience, bring you the most relevant content, show you the most useful ads, and to help report any issues with our site. You can update your preferences at any time by visiting preferences. By selecting Accept, you consent to our use of cookies. To learn more about how your data is used, visit our cookie policy.
$1.05 USD
